acecainide has been researched along with Arrhythmia in 41 studies
Acecainide: A major metabolite of PROCAINAMIDE. Its anti-arrhythmic action may cause cardiac toxicity in kidney failure.
N-acetylprocainamide : A benzamide obtained via formal condensation of 4-acetamidobenzoic acid and 2-(diethylamino)ethylamine.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The actions of acetylprocainamide, the major metabolite of procainamide in man, were studied in a placebo-controlled oral-dose-ranging trial in 16 persons with arrhythmias." | 9.05 | The clinical pharmacology and antiarrhythmic efficacy of acetylprocainamide in patients with arrhythmias. ( Drayer, D; Ellis, G; Hayes, J; Kluger, J; Lloyd, V; Reidenberg, M; Tyberg, T, 1980) |
| "Four patients with chronic ventricular arrhythmias, shown to respond over the short term to N-acetylprocainamide (NAPA), were treated for between 3 and 4 yr with NAPA, and 24-hr ambulatory ECGs were obtained monthly to monitor their responses." | 9.05 | Efficacy and safety of N-acetylprocainamide in long-term treatment of ventricular arrhythmias. ( Atkinson, AJ; Chao, GC; Kushner, W; Lertora, JJ; Nevin, MJ, 1983) |
| "Procainamide (PA) has been a mainstay of treatment against acute and chronic supraventricular and ventricular arrhythmias for more than 30 years." | 8.76 | Procainamide: clinical pharmacology and efficacy against ventricular arrhythmias. ( Giardina, EG, 1984) |
| "Procainamide (PA) often applied in cases of ventricular arrhythmias causes numerous cardiac and extracardiac undesirable symptoms." | 7.67 | [New anti-arrhythmia drug. III. Comparative studies of the effects of N-propionylprocainamide, procainamide and N-acetylprocainamide on hemodynamics and cardiac blood flow]. ( Kusowska, J; Polakowski, P, 1989) |
| "Acecainide was effective in about one-quarter of patients refractory to other antiarrhythmic drugs." | 6.38 | Acecainide (N-acetylprocainamide). A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cardiac arrhythmias. ( Brogden, RN; Harron, DW, 1990) |
| "The actions of acetylprocainamide, the major metabolite of procainamide in man, were studied in a placebo-controlled oral-dose-ranging trial in 16 persons with arrhythmias." | 5.05 | The clinical pharmacology and antiarrhythmic efficacy of acetylprocainamide in patients with arrhythmias. ( Drayer, D; Ellis, G; Hayes, J; Kluger, J; Lloyd, V; Reidenberg, M; Tyberg, T, 1980) |
| "Eleven patients with chronic ventricular arrhythmias took part in a study of N-acetylprocainamide (NAPA), the major metabolite of procainamide, in order to characterize further NAPA's clinical pharmacology and antiarrhythmic action." | 5.05 | Clinical pharmacology and antiarrhythmic efficacy of N-acetylprocainamide. ( Jaillon, P; Kates, RE; Peters, F; Winkle, RA, 1981) |
| "Four patients with chronic ventricular arrhythmias, shown to respond over the short term to N-acetylprocainamide (NAPA), were treated for between 3 and 4 yr with NAPA, and 24-hr ambulatory ECGs were obtained monthly to monitor their responses." | 5.05 | Efficacy and safety of N-acetylprocainamide in long-term treatment of ventricular arrhythmias. ( Atkinson, AJ; Chao, GC; Kushner, W; Lertora, JJ; Nevin, MJ, 1983) |
| "Although procainamide (PA) has been widely used to treat patients with both ventricular and supraventricular arrhythmias since 1951, more than twenty years elapsed before N-acetylprocainamide (NAPA) was identified as a major PA metabolite and shown in PA-treated patients to have plasma concentrations generally equaling or being 2 to 3 times greater than those of the parent drug." | 4.77 | Comparison of the pharmacokinetic and pharmacodynamic properties of procainamide and N-acetylprocainamide. ( Atkinson, AJ; Piergies, AA; Ruo, TI, 1988) |
| "Procainamide (PA) has been a mainstay of treatment against acute and chronic supraventricular and ventricular arrhythmias for more than 30 years." | 4.76 | Procainamide: clinical pharmacology and efficacy against ventricular arrhythmias. ( Giardina, EG, 1984) |
| "Procainamide is a useful agent for management of ventricular arrhythmia, however its disposition and appropriate dosing during extracorporeal membrane oxygenation (ECMO) is unknown." | 4.31 | Procainamide pharmacokinetics during extracorporeal membrane oxygenation. ( Rosenbaum, AN; Vollmer, NJ; Wieruszewski, PM; Wittwer, ED, 2023) |
| "A patient on chronic ambulatory peritoneal dialysis (CAPD) was treated with procainamide for control of ventricular arrhythmias." | 3.67 | Use of procainamide in chronic ambulatory peritoneal dialysis: report of a case. ( Kroboth, PD; Mitchum, K; Puschett, JB, 1984) |
| "N-Acetylprocainamide (NAPA), a class III antiarrhythmic drug, caused torsade de pointes in a 72 year old woman who had this arrhythmia on two previous occasions while being treated with quinidine and disopyramide." | 3.67 | Torsade de pointes induced by N-acetylprocainamide. ( Asada, A; Atkinson, AJ; Bowsher, DJ; Chow, MJ; Kushner, W; Murphy, JJ; Piergies, AA; Ruo, TI; Talano, JV, 1984) |
| "We attempted to correlate clinical response with the effects of N-acetylprocainamide (NAPA) on the QT interval in five patients with stable chronic ventricular arrhythmias." | 3.67 | Effect kinetics of N-acetylprocainamide-induced QT interval prolongation. ( Atkinson, AJ; Belknap, SM; Jansyn, EM; Piergies, AA; Ruo, TI, 1987) |
| "Procainamide (PA) often applied in cases of ventricular arrhythmias causes numerous cardiac and extracardiac undesirable symptoms." | 3.67 | [New anti-arrhythmia drug. III. Comparative studies of the effects of N-propionylprocainamide, procainamide and N-acetylprocainamide on hemodynamics and cardiac blood flow]. ( Kusowska, J; Polakowski, P, 1989) |
| "Acetylprocainamide was used to treat 11 patients with previous procainamide-induced lupus syndrome for their cardiac arrhythmias." | 3.66 | Acetylprocainamide therapy in patients with previous procainamide-induced lupus syndrome. ( Drayer, DE; Kluger, J; Lahita, R; Reidenberg, MM, 1981) |
| "Nineteen patients whose arrhythmias were initially suppressed with acetylprocainamide underwent long-term treatment with this drug." | 3.66 | Long-term antiarrhythmic therapy with acetylprocainamide. ( Drayer, DE; Kluger, J; Leech, S; Lloyd, V; Reidenberg, MM, 1981) |
| "Kinetics of and clinical responses to N-acetylprocainamide (NAPA) were evaluated in 10 patients with chronic ventricular arrhythmias who had not responded to usual doses of currently available antiarrhythmic drugs." | 3.66 | N-Acetylprocainamide kinetics and clinical response during repeated dosing. ( Cohen, J; Gaarder, T; Hurst, A; Jelliffe, RW; Rodman, JH, 1982) |
| "The pharmacokinetics and development of antinuclear antibodies (ANAs) during procainamide (PA) therapy were studied in 35 patients with ventricular arrhythmias." | 3.66 | Significance of acetylator phenotype in pharmacokinetics and adverse effects of procainamide. ( Leskinen, O; Metsä-Ketelä, T; Ruosteenoja, R; Ylitalo, P, 1983) |
| "Two patients with chronic renal failure developed transient sinus node dysfunction requiring insertion of a temporary pacemaker while receiving procainamide to control ventricular arrhythmias." | 3.66 | Procainamide-induced sinus node dysfunction in patients with chronic renal failure. ( Friedman, HS; Kim, HG, 1979) |
| " The mean half-life of elimination after a single 500 mg dose of acecainide was 7." | 2.65 | Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: comparison with procainamide. ( Higgins, SB; Oates, JA; Reele, SB; Roden, DM; Smith, RF; Wilkinson, GR; Woosley, RL, 1980) |
| "Many sudden deaths are presumed to be due to an arrhythmia, but the drugs best known for antiarrhythmic activity, the local anesthetic agents, have not been suitable prophylactic agents because of their toxicities and other undesirable pharmacologic characteristics." | 2.65 | Selection of an antiarrhythmic drug for a sudden-death-prevention trial. ( Duff, HJ; Oates, JA; Roden, DM; Woosley, RL, 1982) |
| "Acecainide was effective in about one-quarter of patients refractory to other antiarrhythmic drugs." | 2.38 | Acecainide (N-acetylprocainamide). A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cardiac arrhythmias. ( Brogden, RN; Harron, DW, 1990) |
| "One patient had greater arrhythmia suppression when NAPA and procainamide were combined than when either was administered alone." | 1.28 | Pharmacokinetic and pharmacodynamic interaction of N-acetyl procainamide and procainamide in humans. ( Funck-Brentano, C; Light, RT; Lineberry, MD; Roden, DM; Woosley, RL; Wright, GM, 1989) |
| "A patient developed acute renal failure while receiving oral procainamide (PA)." | 1.27 | Procainamide toxicity in a patient with acute renal failure. ( Brady, ME; Rosansky, SJ, 1986) |
| "To assess the efficacy, plasma drug concentrations and adverse effects of a new sustained release preparation of procainamide, 33 patients with heart disease were studied in an acute dose-ranging protocol and a chronic treatment protocol." | 1.26 | Efficacy, plasma concentrations and adverse effects of a new sustained release procainamide preparation. ( Bigger, JT; Fenster, PE; Giardina, EG; Marcus, FI; Mayersohn, M; Perrier, D, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 38 (92.68) | 18.7374 |
| 1990's | 2 (4.88) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (2.44) | 2.80 |
| Authors | Studies |
|---|---|
| Vollmer, NJ | 1 |
| Wittwer, ED | 1 |
| Rosenbaum, AN | 1 |
| Wieruszewski, PM | 1 |
| Sanna, GP | 1 |
| Giardina, EG | 2 |
| Raja, R | 1 |
| Kramer, M | 1 |
| Alvis, R | 1 |
| Goldstein, S | 1 |
| DeLosAngeles, A | 1 |
| Kluger, J | 4 |
| Drayer, D | 2 |
| Reidenberg, M | 2 |
| Ellis, G | 1 |
| Lloyd, V | 2 |
| Tyberg, T | 1 |
| Hayes, J | 1 |
| Gallaher, C | 1 |
| Henderson, GL | 1 |
| Low, RI | 1 |
| Amsterdam, EA | 1 |
| Mason, DT | 1 |
| Roden, DM | 6 |
| Reele, SB | 1 |
| Higgins, SB | 1 |
| Wilkinson, GR | 1 |
| Smith, RF | 1 |
| Oates, JA | 2 |
| Woosley, RL | 5 |
| Fenster, PE | 1 |
| Bigger, JT | 1 |
| Mayersohn, M | 1 |
| Perrier, D | 1 |
| Marcus, FI | 1 |
| Winkle, RA | 1 |
| Jaillon, P | 1 |
| Kates, RE | 1 |
| Peters, F | 1 |
| Dangman, KH | 1 |
| Hoffman, BF | 1 |
| Drayer, DE | 2 |
| Reidenberg, MM | 2 |
| Lahita, R | 2 |
| González, ER | 1 |
| Leech, S | 1 |
| Vyden, JK | 1 |
| Duff, HJ | 1 |
| Rodman, JH | 1 |
| Hurst, A | 1 |
| Gaarder, T | 1 |
| Cohen, J | 1 |
| Jelliffe, RW | 1 |
| Engel, TR | 1 |
| Pittard, WB | 1 |
| Glazier, H | 1 |
| Atkinson, AJ | 4 |
| Lertora, JJ | 1 |
| Kushner, W | 2 |
| Chao, GC | 1 |
| Nevin, MJ | 1 |
| Sung, RJ | 1 |
| Juma, Z | 1 |
| Saksena, S | 1 |
| Vlasses, PH | 1 |
| Rocci, ML | 1 |
| Porrini, KA | 1 |
| Greenspon, AJ | 1 |
| Ferguson, RK | 1 |
| Ylitalo, P | 1 |
| Ruosteenoja, R | 1 |
| Leskinen, O | 1 |
| Metsä-Ketelä, T | 1 |
| Kroboth, PD | 1 |
| Mitchum, K | 1 |
| Puschett, JB | 1 |
| Chow, MJ | 1 |
| Piergies, AA | 3 |
| Bowsher, DJ | 1 |
| Murphy, JJ | 1 |
| Ruo, TI | 3 |
| Asada, A | 1 |
| Talano, JV | 1 |
| Matusewicz, W | 1 |
| Orszulak, DE | 1 |
| Yang, BB | 1 |
| Abel, RB | 1 |
| Uprichard, AC | 1 |
| Smithers, JA | 1 |
| Forgue, ST | 1 |
| Kim, HG | 1 |
| Friedman, HS | 1 |
| Harron, DW | 1 |
| Brogden, RN | 1 |
| Rosansky, SJ | 1 |
| Brady, ME | 1 |
| Singh, BN | 2 |
| Feld, G | 1 |
| Nademanee, K | 2 |
| Yamaji, A | 1 |
| Kataoka, K | 1 |
| Oishi, M | 1 |
| Kanamori, N | 1 |
| Hiraoka, E | 1 |
| Mishima, M | 1 |
| Jansyn, EM | 1 |
| Belknap, SM | 1 |
| Funck-Brentano, C | 1 |
| Light, RT | 1 |
| Lineberry, MD | 1 |
| Wright, GM | 1 |
| Kusowska, J | 2 |
| Polakowski, P | 1 |
6 reviews available for acecainide and Arrhythmia
| Article | Year |
|---|---|
Procainamide: clinical pharmacology and efficacy against ventricular arrhythmias.
Topics: Acecainide; Administration, Oral; Animals; Arrhythmias, Cardiac; Electrocardiography; Heart; Humans; | 1984 |
The electropharmacology of acute drug testing using pacemakers.
Topics: Acecainide; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Dogs; Electrophysiology; Heart Co | 1982 |
[Clinical pharmacology of procainamide and its active metabolite -N-acetylprocainamide].
Topics: Acecainide; Animals; Arrhythmias, Cardiac; Biological Availability; Biotransformation; Half-Life; Hu | 1984 |
Theoretical basis for interest in acetylprocainamide and clinical experiences with this new antiarrhythmic agent.
Topics: Acecainide; Acetylation; Animals; Arrhythmias, Cardiac; Isomerism; Kinetics; Procainamide | 1979 |
Acecainide (N-acetylprocainamide). A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cardiac arrhythmias.
Topics: Acecainide; Arrhythmias, Cardiac; Humans; Procainamide | 1990 |
Comparison of the pharmacokinetic and pharmacodynamic properties of procainamide and N-acetylprocainamide.
Topics: Acecainide; Arrhythmias, Cardiac; Electrophysiology; Hemodynamics; Humans; Procainamide | 1988 |
6 trials available for acecainide and Arrhythmia
| Article | Year |
|---|---|
The clinical pharmacology and antiarrhythmic efficacy of acetylprocainamide in patients with arrhythmias.
Topics: Acecainide; Adult; Aged; Arrhythmias, Cardiac; Blood Pressure; Dose-Response Relationship, Drug; Ech | 1980 |
Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: comparison with procainamide.
Topics: Acecainide; Adolescent; Adult; Aged; Ambulatory Care; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; | 1980 |
Clinical pharmacology and antiarrhythmic efficacy of N-acetylprocainamide.
Topics: Acecainide; Adult; Aged; Arrhythmias, Cardiac; Coronary Disease; Dose-Response Relationship, Drug; E | 1981 |
Selection of an antiarrhythmic drug for a sudden-death-prevention trial.
Topics: Acecainide; Amiodarone; Anilides; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Benzeneac | 1982 |
Efficacy and safety of N-acetylprocainamide in long-term treatment of ventricular arrhythmias.
Topics: Acecainide; Aged; Ambulatory Care; Analysis of Variance; Arrhythmias, Cardiac; Chromatography, High | 1983 |
Pharmacokinetic and pharmacodynamic comparisons of twice daily and four times daily formulations of procainamide in patients with frequent ventricular premature depolarization.
Topics: Acecainide; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chemistry, Pharmaceutical; Cross-Over Stud | 1996 |
29 other studies available for acecainide and Arrhythmia
| Article | Year |
|---|---|
Procainamide pharmacokinetics during extracorporeal membrane oxygenation.
Topics: Acecainide; Adult; Arrhythmias, Cardiac; Extracorporeal Membrane Oxygenation; Humans; Procainamide; | 2023 |
New drugs in the management of ventricular arrhythmias.
Topics: Acecainide; Amiodarone; Anilides; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Benzeneac | 1984 |
Resin hemoperfusion for severe N-acetylprocainamide toxicity in patients with renal failure.
Topics: Acecainide; Aged; Arrhythmias, Cardiac; Female; Hemoperfusion; Humans; Kidney Failure, Chronic; Male | 1984 |
Comparison of high-performance liquid chromatography with an enzyme multiplied immunoassay technique for the analysis of serum procainamide and N-acetylprocainamide.
Topics: Acecainide; Arrhythmias, Cardiac; Chromatography, High Pressure Liquid; Drug Interactions; Humans; I | 1980 |
Efficacy, plasma concentrations and adverse effects of a new sustained release procainamide preparation.
Topics: Acecainide; Acetylation; Adult; Aged; Anti-Arrhythmia Agents; Antibodies, Antinuclear; Arrhythmias, | 1980 |
In vivo and in vitro antiarrhythmic and arrhythmogenic effects of N-acetyl procainamide.
Topics: Acecainide; Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Coronary Vesse | 1981 |
Acetylprocainamide therapy in patients with previous procainamide-induced lupus syndrome.
Topics: Acecainide; Aged; Antibodies, Antinuclear; Arrhythmias, Cardiac; Female; Humans; Lupus Vulgaris; Mal | 1981 |
Alter drug structure--avert induced lupus.
Topics: Acecainide; Arrhythmias, Cardiac; Female; Humans; Lupus Erythematosus, Systemic; Male; Procainamide; | 1981 |
Long-term antiarrhythmic therapy with acetylprocainamide.
Topics: Acecainide; Acetylation; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Arthritis, Rheum | 1981 |
Acecainide for ventricular arrhythmias.
Topics: Acecainide; Arrhythmias, Cardiac; Heart Ventricles; Humans; Procainamide | 1982 |
N-Acetylprocainamide kinetics and clinical response during repeated dosing.
Topics: Acecainide; Aged; Arrhythmias, Cardiac; Dose-Response Relationship, Drug; Electrocardiography; Femal | 1982 |
Procainamide excretion in human milk.
Topics: Acecainide; Adult; Arrhythmias, Cardiac; Female; Humans; Infant, Newborn; Male; Milk, Human; Postpar | 1983 |
Electrophysiologic properties and antiarrhythmic mechanisms of intravenous N-acetylprocainamide in patients with ventricular dysrhythmias.
Topics: Acecainide; Adult; Aged; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Cardiac Pacing, Artific | 1983 |
Immediate-release and sustained-release procainamide: bioavailability at steady state in cardiac patients.
Topics: Acecainide; Aged; Arrhythmias, Cardiac; Biological Availability; Capsules; Delayed-Action Preparatio | 1983 |
Importance of metabolites in antiarrhythmic therapy.
Topics: Acecainide; Agranulocytosis; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Encainide; Huma | 1983 |
Significance of acetylator phenotype in pharmacokinetics and adverse effects of procainamide.
Topics: Acecainide; Acetylation; Adult; Aged; Antibodies, Antinuclear; Arrhythmias, Cardiac; Delayed-Action | 1983 |
Use of procainamide in chronic ambulatory peritoneal dialysis: report of a case.
Topics: Acecainide; Acetylation; Arrhythmias, Cardiac; Half-Life; Heart Ventricles; Humans; Kidney; Liver; M | 1984 |
Torsade de pointes induced by N-acetylprocainamide.
Topics: Acecainide; Aged; Arrhythmias, Cardiac; Electrocardiography; Female; Humans; Kinetics; Procainamide; | 1984 |
Procainamide-induced sinus node dysfunction in patients with chronic renal failure.
Topics: Acecainide; Aged; Angina Pectoris; Arrhythmia, Sinus; Arrhythmias, Cardiac; Bradycardia; Female; Hea | 1979 |
Antiarrhythmic drugs. Clinical pharmacology of the old and the new agents.
Topics: Acecainide; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sudden; Delayed-Action | 1985 |
Procainamide toxicity in a patient with acute renal failure.
Topics: Acecainide; Acute Kidney Injury; Administration, Oral; Aged; Arrhythmias, Cardiac; Gentamicins; Hemo | 1986 |
Arrhythmia control by selective lengthening of cardiac repolarization: role of N-acetylprocainamide, active metabolite of procainamide.
Topics: Acecainide; Action Potentials; Animals; Arrhythmias, Cardiac; Depression, Chemical; Dogs; Electrophy | 1986 |
Simultaneous determination of procainamide and N-acetylprocainamide in serum by gas chromatography with nitrogen-selective detection.
Topics: Acecainide; Adult; Arrhythmias, Cardiac; Chromatography, Gas; Humans; Indicators and Reagents; Kinet | 1987 |
Effect kinetics of N-acetylprocainamide-induced QT interval prolongation.
Topics: Acecainide; Aged; Arrhythmias, Cardiac; Electrocardiography; Female; Heart Ventricles; Humans; Kinet | 1987 |
Pharmacokinetic and pharmacodynamic interaction of N-acetyl procainamide and procainamide in humans.
Topics: Acecainide; Acetylation; Adult; Aged; Arrhythmias, Cardiac; Drug Interactions; Electrocardiography; | 1989 |
[A new anti-arrhythmia drug. II. Comparative studies of the effects of a new acyl derivative of procainamide, procainamide and N-acetylprocainamide on blood pressure and the electrocardiogram in rabbits].
Topics: Acecainide; Animals; Arrhythmias, Cardiac; Blood Pressure; Drug Evaluation, Preclinical; Electrocard | 1989 |
[New anti-arrhythmia drug. III. Comparative studies of the effects of N-propionylprocainamide, procainamide and N-acetylprocainamide on hemodynamics and cardiac blood flow].
Topics: Acecainide; Animals; Arrhythmias, Cardiac; Coronary Circulation; Drug Evaluation, Preclinical; Femal | 1989 |
QT prolongation and arrhythmia suppression.
Topics: Acecainide; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Deafness; Death, Sudden; Elect | 1985 |
Control of cardiac arrhythmias by selective lengthening of repolarization: theoretic considerations and clinical observations.
Topics: Acecainide; Action Potentials; Amiodarone; Arrhythmias, Cardiac; Depression, Chemical; Electrocardio | 1985 |